Phase 1 Parkinson's Disease Trial, Recruiting NCT06683365 Sponsor: Craig van Horne, MD, PhD Condition: Parkinson's Disease
Back to Parkinsons Disease

Phase 1 Parkinson's Disease Trial, Recruiting

NCT06683365
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Parkinson's disease (PD) or Multiple System Atrophy (MSA) that is clinically established or clinically probable, based on recognised medical criteria
  • People whose condition has been present for more than 2 years
  • People aged between 40 and 75 years (inclusive)
  • People whose movement symptoms fall within a specific range on standardised rating scales, measured while not taking Parkinson's medications (confirm with trial site for exact score requirements)
  • People whose specific movement symptoms, when tested off medication, do not exceed a certain severity level on particular parts of the Parkinson's rating scale (confirm with trial site for exact score requirements)
  • People who are able and willing to have a type of brain scan called an ioflupane/SPECT scan
  • People who are physically able to undergo a surgical procedure
  • People who are able to complete all planned assessments throughout the trial
  • People who have an accessible sural nerve (a nerve in the lower leg)

Who may not be able to join:

  • People who have previously had brain surgery or surgery specifically for Parkinson's disease
  • People who currently have a significant medical or psychiatric condition, including depression or psychosis
  • People who are currently taking a type of medication called neuroleptics (antipsychotic medicines)
  • People whose ioflupane/SPECT brain scan results do not show a pattern consistent with Parkinson's-related conditions
  • People who are unable to have an MRI scan
  • People where the surgical pathway to the relevant area of the brain is blocked or obstructed
  • People who have significant damage to small blood vessels in the brain
  • People who are taking blood-thinning medications other than aspirin
  • People who are pregnant, breastfeeding, or capable of becoming pregnant and unwilling to use adequate contraception for the duration of the study
  • People whose ability to give informed consent is found to have declined before surgery may be removed from the study by the principal investigator (confirm with trial site for further details)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Craig van Horne, MD, PhD, University of Kentucky

Phone: 859-323-1908

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Craig van Horne, MD, PhD
Registry
ClinicalTrials.gov
Start date
25 February 2025
Est. completion
2 December 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Meet recruitment goal

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov